Business
SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Non-Small Cell Lung Cancer at WCLC Congress 2025
SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced that two abstracts for iza-bren (izalontamab brengitecan), a potentially first-in-class EGFRxHER3 bispecific antibody drug conjugate (ADC), will be presented at the World Conference on Lung Cancer (WCLC) 2025 Annual Meeting taking place September 6 – 9 in Barcelona, Spain. Iza-bren is jointly developed by SystImmune and Bristol Myers Squibb under a collaboration and exclusive license agreement in territories o
About this update from Bristol-myers Squibb Company
[{"type":"list","items":[{"val":[{"type":"text","content":"Safety & efficacy of iza-bren, an EGFRxHER3 bispecific topoisomerase inhibitor- based antibody-drug conjugate (ADC), in patients with EGFR mutated Non-Small Cell Lung Cancer (NSCLC), both as monotherapy and in combination with Osimertinib will be presented ","length":260,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":260,"olType":false},{"type":"text","content":"REDMOND, Wash., Sept. 2, 2025 /PRNewswire/ -- SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced that two abstracts for iza-bren (izalontamab brengitecan), a potentially first-in-class EGFRxHER3 bispecific antibody drug conjugate (ADC), will be presented at the World Conference on Lung Cancer (WCLC) 2025 Annual Meeting taking place September 6 – 9 in Barcelona, Spain. Iza-bren is jointly developed by SystImmune and Bristol Myers Squibb under a collaboration and exclusive license agreement in territories outside of China.","length":562,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/SystImmune Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/SystImmune Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":200,"url":"https://media.zenfs.com/en/prnewswire.com/a2c51215c5ec63b757111724cd5e99fd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/t9BSUp404OjD9NcuWC2l6w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/a2c51215c5ec63b757111724cd5e99fd","width":400,"height":200}},"href":"https://mma.prnewswire.com/media/2053215/SystImmune_Logo_1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The safety and efficacy results of iza-bren as a monotherapy and in combination with Osimertinib in patients with advanced stages of EGFR mutated Non-Small Cell Lung Cancer will be presented at WCLC. The data highlights the continued progress of iza-bren clinical development and builds upon the previously reported clinical activity in lung, breast, and bladder cancer patients at ASCO, ESMO, and SABCS in 2023, 2024 and 2025.","length":427,"tagName":"p"},{"type":"text","content":""These data further enhance our confidence in iza-bren's clinical activity across a wide range of tumors," said Jonathan Cheng, M.D., Chief Medical Officer of SystImmune. "We are particularly exc...